SEARCH:   Advanced

Blood, 15 February 2004, Vol. 103, No. 4, pp. 1472-1474. Prepublished online as a Blood First Edition Paper on October 16, 2003; DOI 10.1182/blood-2003-07-2548. This Article Abstract Full Text (PDF) All Versions of this Article: 2003-07-2548v1 103/4/1472    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Farag, S. S. Articles by Byrd, J. C. Search for Related Content PubMed PubMed Citation Articles by Farag, S. S. Articles by Byrd, J. C. Related Collections Immunobiology Neoplasia Immunotherapy Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA FcRIIIa and FcRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia Sherif S. Farag, Ian W. Flinn, Rama Modali, Teresa A. Lehman, Donn Young, and John C. Byrd From the Division of Hematology-Oncology and the Department of Biostatistics, Ohio State University, Columbus; the Division of Hematologic Malignancies, Johns Hopkins University, Baltimore, MD; and BioServe Biotechnologies, Laurel, MD.    Abstract Top Abstract Introduction Patients, materials, and methods Results Discussion References   In follicular lymphoma (FL), genomic polymorphisms corresponding to the expression of valine (V) or phenylalanine (F) at amino acid 158 of FcRIIIa alter the binding affinity of immunoglobulin G1 (IgG1) to the receptor and have been associated with varied responses to rituximab. We examined FcRIIIa polymorphisms of 30 CLL patients with the phenotypes V/V (n = 6), V/F (n = 12), and F/F (n = 12) treated with thrice-weekly rituximab (375 mg/m2) for 4 weeks to correlate polymorphism type with infusion toxicity and response. Infusion toxicity (grade 3 or greater or hypoxia/hypotension requiring transient cessation of therapy) was observed equally among the groups (V/V, 50%; V/F, 33%; F/F, 41.6%; P = .78). The response to rituximab was also similar among the different polymorphism phenotypes (V/V, 33%; V/F, 41.6%; F/F, 50%). These data suggest that FcRIIIa polymorphisms are not predictive of response in CLL and that, unlike the case with FL, mechanisms of tumor clearance other than antibody-dependent cellular cytotoxicity may be more important.    Introduction Top Abstract Introduction Patients, materials, and methods Results Discussion References   Rituximab is a chimeric monoclonal antibody directed against CD20, an antigen found most B-cell malignancies, including non-Hodgkin follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). As a single agent, rituximab induces objective responses in more than 50% of FL and CLL patients with minimal toxicity because of its B-cell selectivity.1-4 These favorable results have led to considerable interest in combining rituximab with other agents in FL and CLL. However, understanding how rituximab mediates its in vivo biologic effects in these diseases is likely to enhance the effective implementation of combination therapy. Multiple mechanisms have been proposed for the activity of rituximab, including antibody-dependent cellular cytotoxicity (ADCC),5,6 complement-dependent cytotoxicity (CDC),6,7 and a direct proapoptotic effect.8,9 Although F(ab')2 rituximab homodimers were shown to be effective in inducing apoptosis of B-cell lymphoma cell lines in vitro,10 other works have recently established that ADCC is important as a predominant mechanism of lymphoma cell clearance and that Fc receptors (FcRs) are critical for the in vivo actions of rituximab in non-Hodgkin lymphoma (NHL).11 In a xenograft model of human lymphoma, knocking out the FcR loci in mice showed a complete abrogation of response to rituximab.11 In contrast, knocking out the inhibitory FcRIIb in mice resulted in enhanced response to rituximab in the same xenograft model.11 In addition, the recent demonstration in NHL patients that the response to rituximab is dependent on specific FcRIIIa polymorphisms supports the importance of ADCC in the in vivo actions of rituximab.12 The activating FcR on natural killer (NK) cells and monocytes (FcRIIIa) and on monocytes (FcRIIa) mediates ADCC. Genomic polymorphism corresponding to phenotype expression of valine (V) or phenylalanine (F) at amino acid 158 on the FcRIIIa greatly influences the affinity of IgG1 to the Fc receptor. Studies have demonstrated the stronger binding of antibody to homozygous FcRIIIa-158V NK cells than to homozygous FcRIIIa-158P or heterozygous NK cells.13,14 Similarly, polymorphism related to the expression of histidine (H) or arginine (R) at amino acid 131 in FcRIIa affects the binding affinity of IgG1.15 Forty-nine patients with previously untreated FL, patients homozygous for FcRIIIa-158V (V/V), had a significantly higher (100%) clinical response rate than those with heterozygous (V/F) or homozygous phenylalanine (F/F) genotype (67%).12 Furthermore, polymerase chain reaction (PCR) detection of bcl-2 rearranged cells was significantly lower in the homozygous V/V group. In contrast, the FcRIIa-131 polymorphism was not associated with response to rituximab. It is possible, however, that the relative importance of ADCC as a mechanism for the activity of rituximab may differ in B-cell malignancies other than NHL. CLL differs significantly from FL from an immunophenotypic15,16 and a genomic17 standpoint, with most tumor cells having dim CD20 antigen expression. Studies have demonstrated that CLL cells are often resistant to complement-mediated cytotoxicity6,18 and that, in responding patients receiving rituximab,19 caspase-dependent apoptosis may be the predominant mechanism by which tumor cell elimination occurs. Although the effector-to-tumor cell ratio and the TH2 cytokine profile in CLL do not favor effective ADCC, the importance of FcRIIIa has not been explored in CLL. Herein, we examine the importance of FcRIIIa and FcRIIa polymorphisms to response and toxicity observed with rituximab treatment in CLL.    Patients, materials, and methods Top Abstract Introduction Patients, materials, and methods Results Discussion References   Patient samples and cell processing Patients were enrolled in this previously reported, institutional review board (Walter Reed Army Medical Center, Johns Hopkins Oncology Center, and The Ohio State University)–approved, multicenter trial.4 All patients gave written, informed consent before participation. Patients were required to have histologically documented CLL as defined by the modified National Cancer Institute (NCI) criteria20 or to have small lymphocytic lymphoma as defined by the International Working Formulation classification.21 Treatment included stepped-up administration of thrice-weekly rituximab for 4 consecutive weeks, as previously described.4 Response to rituximab was judged 2 months after therapy according to the modified National Cancer Institute (NCI) criteria.20 Infusion toxicity was defined by the presence of hypoxemia, hypotension, or dyspnea, which required transient discontinuation of the infusion and supportive intervention. Cells were obtained before rituximab treatment, and mononuclear cells were isolated from blood using density-gradient centrifugation (Ficoll-Hypaque Plus; Pharmacia Biotech, Piscataway, NJ). Cells were then viably cryopreserved in 10% dimethyl sulfoxide (DMSO), 40% fetal calf serum, and 50% RPMI medium. Analysis of FcRIIIa and FcRIIa polymorphisms Pretreatment samples for analyses of V/F 158 FcRIIIa and FcRIIa 131 H/R polymorphisms were available for 30 (90%) of 33 patients enrolled in this trial. DNA was extracted using the QIAamp kit according to the manufacturer's instructions (Qiagen, Valencia, CA). Assessment of the of FcRIIIa and FcRIIa polymorphisms was performed as previously described.12 All samples were analyzed in duplicate, with identical results. Statistical analysis Pretreatment clinical features, observed toxicity, and response to therapy among the polymorphism groups were compared using 2 analysis for categorical data and the nonparametric Kruskal-Wallis test for continuous data. A P value of .05 was considered statistically significant.    Results Top Abstract Introduction Patients, materials, and methods Results Discussion References   Pretreatment features of the 30 patients separated according to FcRIIIa polymorphism group are shown in Table 1. Six (20%) and 12 (40%) patients were homozygous for the V/V 158 FcRIIIa and the F/F 158-FcRIIIa polymorphisms, respectively. Although more male patients were homozygous for FcRIIIa F/F, there was no other significant difference in the pretreatment clinical characteristics among the groups. Of the 30 patients included, 12 patients experienced infusion toxicity that required the temporary cessation of rituximab therapy and intervention. The incidence of infusion toxicity was similar (50%, 33%, and 42%; P = .78) among the 3 different 158-FcRIIIa polymorphism groups. Similarly, among the 13 patients who achieved partial response to thrice-weekly rituximab therapy, there was no significant difference in response rate between the V/V, V/F, and F/F 158 FcRIIIa polymorphism groups, with responses seen in 33% (95% confidence interval [CI], 4%-78%), 42% (95% CI, 15%-72%), and 50% (95% CI, 21%-79%), respectively (P = .70). Although the result is limited by the small number of cases studied within each subgroup, resulting in wide confidence intervals for the estimate of response to rituximab, the directional trend in our result was opposite what might have been expected based on the increased affinity of the V/V phenotype FcRIIIa for the antibody. Table 2 shows the clinical baseline characteristics of the same 30 patients analyzed using the 131-FcRIIa polymorphism phenotype. Similar to the results observed for the 158-FcRIIIa polymorphism, there were no significant differences in infusion toxicity or response rate among the 3 groups. View this table: [in this window] [in a new window]   Table 1.. Clinical features of CLL patients by FcRIIIa polymorphism type   View this table: [in this window] [in a new window]   Table 2.. Clinical features of CLL patients by FcRIIa polymorphism type      Discussion Top Abstract Introduction Patients, materials, and methods Results Discussion References   Our findings are in contrast to the FL results reported by Cartron et al,12 which showed that the high-affinity 158-FcRIIIa V/V polymorphism was associated with the highest response rate in patients treated with rituximab.12 Although the numbers of CLL patients in our series was smaller, the subset of patients with the high-affinity polymorphism had the lowest response rate. Several explanations for these findings are possible, including a different mechanism of action of rituximab in CLL compared with lymphoma or a varied patient population among the patient groups analyzed. In FL, preclinical animal studies,11 the FcRIIIa polymorphism studies of Cartron et al,12 and higher response rates observed in studies that combine rituximab with agents that enhance ADCC22 all support ADCC as an important mechanism for the activity of rituximab. In contrast, however, our results suggest that ADCC may be a less important mechanism in CLL. The reduced expression of CD20 on the neoplastic cells of CLL compared with FL, or the presence of higher levels of soluble CD20 in CLL, may significantly reduce the efficiency of rituximab in mediating ADCC in spite of the higher affinity of FcRIIIa and FcRIIa and may contribute to the lack of observed effect of FcR polymorphisms on response. In addition, it is possible that ADCC is the more important mechanism for clearance of neoplastic B cells in lymph nodes, predominantly involved in FL, compared with blood and bone marrow, which are more commonly involved in CLL. Although we have no direct data to support or refute these possibilities, a plausible alternative explanation is that rituximab acts by different mechanisms in CLL. We previously demonstrated in vivo activation of the intrinsic pathway of apoptosis in CLL patients responding to rituximab.19 In addition, several cellular and genetic factors that inhibit apoptosis in CLL also diminish response to rituximab. The role of CDC is also less likely because CLL cells often dimly express CD20 and overexpress CD55 and CD59, which prevents CDC.6,18 Further diminishing the major role of CDC in CLL is the lack of correlation with response to CD55 and CD59, shown in another study.23 Indeed, this study, combined with the results of other studies in CLL in which cellular23 and genetic24 features that disrupt apoptosis are associated with diminished response, provides support for the hypothesis that signaling and apoptosis may contribute more to the therapeutic efficacy of rituximab in CLL than ADCC or CDC. These results provide justification for the emphasis on disease-specific studies to determine the mechanisms of how specific monoclonal antibody therapies work in vivo.    Footnotes   Submitted July 29, 2003; accepted October 7, 2003. Prepublished online as Blood First Edition Paper, October 16, 2003; DOI 10.1182/blood-2003-07-2548. Supported in part by the National Cancer Institute (grant P01 CA95426-01A1), the Sidney Kimmel Cancer Research Foundation, the Leukemia and Lymphoma Society of America, and the D. Warren Brown Foundation. Two authors (T.A.L. and R.M.) have declared a financial interest in performing Fc polymorphism analysis (BioServe Biotechnologies). The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734. Reprints: John C. Byrd, Division of Hematology-Oncology, Starling Loving Hall, Rm 302, The Ohio State University, Columbus, OH 43210; e-mail: byrd-3{at}medctr.osu.edu.    References Top Abstract Introduction Patients, materials, and methods Results Discussion References   Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1997;15: 3266-3274.[Abstract] McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16: 2825-2833.[Abstract] O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001;19: 2165-2170.[Abstract/Free Full Text] Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001;19: 2153-2164.[Abstract/Free Full Text] Reff M, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83: 435-445.[Abstract/Free Full Text] Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000;95: 3900-3908.[Abstract/Free Full Text] Harjunpaa A, Junnikkala S, Meri S, et al. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol. 2000;51: 634-641.[CrossRef][Medline] [Order article via Infotrieve] Maloney D, Smith B. The anti-tumor effect of monoclonal anti-CD20 antibody (MAB) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines [abstract]. Blood. 1996;88: 637. Hofmeister JK, Cooney D, Coggeshall KM. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis. 2000;26: 133-143.[CrossRef][Medline] [Order article via Infotrieve] Ghetie MA, Bright H, Vitetta ES. Homodimers but not monomers of Rituxin (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood. 2001;97: 1392-1398.[Abstract/Free Full Text] Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6: 443-446.[CrossRef][Medline] [Order article via Infotrieve] Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcRIIIa gene. Blood. 2002;99: 754-758.[Abstract/Free Full Text] Wu J, Edberg JC, Radecha PB, et al. A novel polymorphism of FcRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest. 1997;100: 1059-1070.[Medline] [Order article via Infotrieve] Koene HR, Kleijer M, Algra J, et al. FcRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcRIIIa, independently of the FcRIIIa-48L/R/H phenotype. Blood. 1997; 90: 1109-1114.[Abstract/Free Full Text] Binstadt BA, Geha RS, Bonilla F. IgG Fc receptor polymorphisms in human disease: implications for intravenous immunglobulin therapy. J Allergy Clin Immunol. 2003;111: 697-703.[CrossRef][Medline] [Order article via Infotrieve] Kay NE, Hamblin TJ, Jelinek DF, et al. Chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program). 2002: 193-213. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194: 1639-1647.[Abstract/Free Full Text] Bellosillo B, Villamor N, Lopez-Guillermo A, et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood. 2001; 98: 2771-2777.[Abstract/Free Full Text] Byrd JC, Kitada S, Flinn IW, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002;99: 1038-1043.[Abstract/Free Full Text] Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87: 4990-4997.[Free Full Text] Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17: 3835-3849.[Abstract/Free Full Text] Ansell SM, Witzig TE, Kurtin PJ, et al. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood. 2002;99: 67-74.[Abstract/Free Full Text] Bannerji R, Kitada S, Flinn IW, et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol. 2003;21: 1466-1471.[Abstract/Free Full Text] Byrd J, Smith L, Hackbarth M, et al. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia predict response to rituximab. Cancer Res. 2003;63: 36-38.[Abstract/Free Full Text] CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: C. Meyer zum Buschenfelde, Y. Feuerstacke, K. S. Gotze, K. Scholze, and C. Peschel GM1 Expression of Non-Hodgkin's Lymphoma Determines Susceptibility to Rituximab Treatment Cancer Res., July 1, 2008; 68(13): 5414 - 5422. [Abstract] [Full Text] [PDF] S. Varchetta, N. Gibelli, B. Oliviero, E. Nardini, R. Gennari, G. Gatti, L. S. Silva, L. Villani, E. Tagliabue, S. Menard, et al. Elements Related to Heterogeneity of Antibody-Dependent Cell Cytotoxicity in Patients Under Trastuzumab Therapy for Primary Operable Breast Cancer Overexpressing Her2 Cancer Res., December 15, 2007; 67(24): 11991 - 11999. [Abstract] [Full Text] [PDF] E. Oflazoglu, I. J. Stone, K. A. Gordon, I. S. Grewal, N. van Rooijen, C.-L. Law, and H.-P. Gerber Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30 Blood, December 15, 2007; 110(13): 4370 - 4372. [Abstract] [Full Text] [PDF] B. Z. Alizadeh, G. Valdigem, M. J.H. Coenen, A. Zhernakova, B. Franke, A. Monsuur, P. L.C.M. van Riel, P. Barrera, T. R.D.J. Radstake, B. O. Roep, et al. Association analysis of functional variants of the FcgRIIa and FcgRIIIa genes with type 1 diabetes, celiac disease and rheumatoid arthritis Hum. Mol. Genet., November 1, 2007; 16(21): 2552 - 2559. [Abstract] [Full Text] [PDF] W. Zhang, M. Gordon, A. M. Schultheis, D. Y. Yang, F. Nagashima, M. Azuma, H.-M. Chang, E. Borucka, G. Lurje, A. E. Sherrod, et al. FCGR2A and FCGR3A Polymorphisms Associated With Clinical Outcome of Epidermal Growth Factor Receptor Expressing Metastatic Colorectal Cancer Patients Treated With Single-Agent Cetuximab J. Clin. Oncol., August 20, 2007; 25(24): 3712 - 3718. [Abstract] [Full Text] [PDF] E. Carlotti, G. A. Palumbo, E. Oldani, D. Tibullo, S. Salmoiraghi, A. Rossi, J. Golay, A. Pulsoni, R. Foa, and A. Rambaldi Fc{gamma}RIIIA and Fc{gamma}RIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab Haematologica, August 1, 2007; 92(8): 1127 - 1130. [Abstract] [Full Text] [PDF] Z. Mitrovic, I. Aurer, I. Radman, R. Ajdukovic, J. Sertic, and B. Labar FC{gamma}RIIIA and FC{gamma}RIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma Haematologica, July 1, 2007; 92(7): 998 - 999. [Abstract] [Full Text] [PDF] H. Horner, C. Frank, C. Dechant, R. Repp, M. Glennie, M. Herrmann, and B. Stockmeyer Intimate Cell Conjugate Formation and Exchange of Membrane Lipids Precede Apoptosis Induction in Target Cells during Antibody-Dependent, Granulocyte-Mediated Cytotoxicity J. Immunol., July 1, 2007; 179(1): 337 - 345. [Abstract] [Full Text] [PDF] J. G. Berdeja, A. Hess, D. M. Lucas, P. O'Donnell, R. F. Ambinder, L. F. Diehl, D. Carter-Brookins, S. Newton, and I. W. Flinn Systemic Interleukin-2 and Adoptive Transfer of Lymphokine-Activated Killer Cells Improves Antibody-Dependent Cellular Cytotoxicity in Patients with Relapsed B-Cell Lymphoma Treated with Rituximab Clin. Cancer Res., April 15, 2007; 13(8): 2392 - 2399. [Abstract] [Full Text] [PDF] C. Bello and E. M. Sotomayor Monoclonal Antibodies for B-Cell Lymphomas: Rituximab and Beyond Hematology, January 1, 2007; 2007(1): 233 - 242. [Abstract] [Full Text] [PDF] J. A. Bowles, S.-Y. Wang, B. K. Link, B. Allan, G. Beuerlein, M.-A. Campbell, D. Marquis, B. Ondek, J. E. Wooldridge, B. J. Smith, et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab Blood, October 15, 2006; 108(8): 2648 - 2654. [Abstract] [Full Text] [PDF] M. Alfonso-Perez, S. Lopez-Giral, N. E. Quintana, J. Loscertales, P. Martin-Jimenez, and C. Munoz Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia J. Leukoc. Biol., June 1, 2006; 79(6): 1157 - 1165. [Abstract] [Full Text] [PDF] Y. Hamaguchi, Y. Xiu, K. Komura, F. Nimmerjahn, and T. F. Tedder Antibody isotype-specific engagement of Fc{gamma} receptors regulates B lymphocyte depletion during CD20 immunotherapy J. Exp. Med., March 20, 2006; 203(3): 743 - 753. [Abstract] [Full Text] [PDF] P. V. Beum, A. D. Kennedy, M. E. Williams, M. A. Lindorfer, and R. P. Taylor The Shaving Reaction: Rituximab/CD20 Complexes Are Removed from Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Cells by THP-1 Monocytes J. Immunol., February 15, 2006; 176(4): 2600 - 2609. [Abstract] [Full Text] [PDF] E A Clark and J A Ledbetter How does B cell depletion therapy work, and how can it be improved? Ann Rheum Dis, November 1, 2005; 64(suppl_4): iv77 - iv80. [Abstract] [Full Text] [PDF] M. Ghielmini, K. Rufibach, G. Salles, L. Leoncini-Franscini, C. Leger-Falandry, S. Cogliatti, M. Fey, G. Martinelli, R. Stahel, A. Lohri, et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK) Ann. Onc., October 1, 2005; 16(10): 1675 - 1682. [Abstract] [Full Text] [PDF] W. G. Wierda, T. J. Kipps, and M. J. Keating Novel Immune-Based Treatment Strategies for Chronic Lymphocytic Leukemia J. Clin. Oncol., September 10, 2005; 23(26): 6325 - 6332. [Abstract] [Full Text] [PDF] D. Ternant, M. Ohresser, C. Thomas, G. Cartron, H. Watier, G. Paintaud, A. Hubsch, M. Spycher, J. Bichler, and S. Miescher Dose-response relationship and pharmacogenetics of anti-RhD monoclonal antibodies Blood, August 15, 2005; 106(4): 1503 - 1505. [Full Text] [PDF] Y. Hamaguchi, J. Uchida, D. W. Cain, G. M. Venturi, J. C. Poe, K. M. Haas, and T. F. Tedder The Peritoneal Cavity Provides a Protective Niche for B1 and Conventional B Lymphocytes during Anti-CD20 Immunotherapy in Mice J. Immunol., April 1, 2005; 174(7): 4389 - 4399. [Abstract] [Full Text] [PDF] P. Carter and C. F. McDonagh Designer Antibody-Based Therapeutics for Oncology Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 147 - 154. [Full Text] [PDF]